Form D · Biotechnology
Phase Genomics, Inc.
Seattle, WA · CIK 0001722760
Offering snapshot reported Mar 21, 2023 · SEC filing
- Reported sold
- $4.75M Offering amount: $6.58M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 14, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 21, 2023 | Initial | $4,754,364 | No comparison | 13 | SEC filing |
| Nov 22, 2017 | Initial | $1,000,001 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity, Debt, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-476536
Convertible Promissory Notes
Source: Form D, filed Mar 21, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ivan Liachko | Director, Executive, Promoter |
| Shawn Sullivan | Executive, Promoter |
| Kayla Young | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1617 8th Ave. North
Seattle, WA, 98109
Seattle, WA, 98109